Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prognostic Value of ctDNA in Waldenström Macroglobulinemia
NCT04893564Recruiting
- Sponsor
- CHU Amiens-Picardie
- Start
- May 2022
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Single-arm trial, sponsored by CHU Amiens-Picardie. Primary endpoint: Progression-Free Survival at 3 years. Started May 2022; status: recruiting.
Beyond the preview
Go deeper on NCT04893564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893564.